

# The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent *In Vitro* Activity against *Cryptococcus neoformans* and *Cryptococcus gattii*

Shawn R. Lockhart,<sup>a</sup> Annette W. Fothergill,<sup>b</sup> Naureen Iqbal,<sup>a</sup> Carol B. Bolden,<sup>a</sup> Nina T. Grossman,<sup>a</sup> Edward P. Garvey,<sup>c</sup> Stephen R. Brand,<sup>c</sup> William J. Hoekstra,<sup>c</sup> Robert J. Schotzinger,<sup>c</sup> Elizabeth Ottinger,<sup>d</sup> Thomas F. Patterson,<sup>b,e</sup> Nathan P. Wiederhold<sup>b</sup>

Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA<sup>a</sup>; University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA<sup>b</sup>; Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA<sup>c</sup>; National Institutes of Health, Therapeutics for Rare and Neglected Diseases, Bethesda, Maryland, USA<sup>d</sup>; South Texas Veterans Health Care System, San Antonio, Texas, USA<sup>e</sup>

The *in vitro* activities of the novel fungal Cyp51 inhibitor VT-1129 were evaluated against a large panel of *Cryptococcus neoformans* and *Cryptococcus gattii* isolates. VT-1129 demonstrated potent activities against both *Cryptococcus* species as demonstrated by low MIC<sub>50</sub> and MIC<sub>90</sub> values. For *C. gattii*, the *in vitro* potency was maintained against all genotypes. In addition, significantly lower geometric mean MICs were observed for VT-1129 than for fluconazole against *C. neoformans*, including isolates with reduced fluconazole susceptibility.

Cryptococcosis remains a clinically significant invasive fungal infection and is associated with significant morbidity and mortality in immunocompromised patients (1–3). Cryptococcal infections are caused by members of the *Cryptococcus neoformans* and *Cryptococcus gattii* species complexes. The two most common manifestations of cryptococcosis are primary pulmonary infection and cryptococcal meningitis. Cryptococcal meningitis is a devastating disease estimated to cause >600,000 deaths worldwide annually (4). The treatment of cryptococcosis typically involves the use of fluconazole, either as the primary therapy for mild to moderate pulmonary involvement or as a consolidation and maintenance therapy following induction therapy with intravenous amphotericin B with or without flucytosine for cryptococcal meningoencephalitis or complicated lung disease (1). VT-1129 (Fig. 1) is a member of a new class of orally available fungal Cyp51 (lanosterol 14- $\alpha$ -demethylase) inhibitors that employ a tetrazole to bind to the active-site heme iron (compound 7c in reference 5). Compared to the approved azole class of antifungal drugs, which contain either a triazole or an imidazole, members of this novel group have greater selectivity for the fungal enzyme than for mammalian cytochrome P450 enzymes (5, 6). Specifically, VT-1129 has been shown to bind tightly to cryptococcal CYP51 recombinant proteins, displaying type II difference spectra essentially identical to those of the approved azole inhibitors, while weakly inhibiting key human CYP450 enzymes (e.g., 3A4, 2C9, and 2C19) (7). Our objective was to measure the *in vitro* activity of VT-1129 against cryptococcal isolates, including members of the *C. neoformans* and *C. gattii* species complexes. The potency of this investigational agent against *C. neoformans* was compared to that of fluconazole; we also included strains with reduced susceptibility to this azole in our study.

VT-1129 powder was provided by Viamet Pharmaceuticals, Inc. (Durham, NC), and fluconazole powder was obtained from Pfizer (New York, NY). Stock solutions were prepared in dimethyl sulfoxide (DMSO) and were stored frozen at  $-70^{\circ}\text{C}$ . Further dilutions were prepared in DMSO and RPMI broth. A total of 180 clinical *C. neoformans* isolates were used in this study, including 100 from HIV-positive patients in South Africa and 80 collected from institutions in North America (8). In addition, 321 isolates of




FIG 1 Chemical structure of VT-1129.

*Cryptococcus gattii* from Africa, Australia, and North America were also used to evaluate the activity of VT-1129 against this species (9, 10). The molecular types of 300 of the *C. gattii* isolates were further identified by multilocus sequence typing (MLST) as previously described (9–11). The MLST data are available within the MLST database (<http://mlst.mycologylab.org/defaultinfo.aspx?page=CG>). Testing was performed by broth microdilution according to the Clinical and Laboratory Standards Institute M27-A3 reference standard (12). Testing was performed independently by the Mycotic Diseases Branch of the Centers for Disease Control and Prevention (CDC) and the Fungus Testing Laboratory of the University of Texas Health Science Center at San Antonio (UTHSCSA). All VT-1129 MIC values were determined visually as the lowest drug concentrations at which there were 50% and 100% inhibitions of growth compared to the growth controls after 72 h of incubation at  $35^{\circ}\text{C}$ . For fluconazole, 50% inhibition

Received 13 November 2015 Returned for modification 6 December 2015


Accepted 12 January 2016

Accepted manuscript posted online 19 January 2016

Citation Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, Brand SR, Hoekstra WJ, Schotzinger RJ, Ottinger E, Patterson TF, Wiederhold NP. 2016. The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent *in vitro* activity against *Cryptococcus neoformans* and *Cryptococcus gattii*. *Antimicrob Agents Chemother* 60:2528–2531. doi:10.1128/AAC.02770-15.

Address correspondence to Nathan P. Wiederhold, [wiederholdn@uthscsa.edu](mailto:wiederholdn@uthscsa.edu).

Copyright © 2016, American Society for Microbiology. All Rights Reserved.



**FIG 2** MIC distributions of VT-1129 and fluconazole against *Cryptococcus neoformans* and *C. gattii* isolates. (A) Percentage of isolates at different VT-1129 and fluconazole MIC levels against 180 *C. neoformans* isolates. (B) Percentage of isolates at different MIC levels for VT-1129 at the lower concentration range tested against 54 *C. neoformans* isolates. (C) Percentage of isolates at different VT-1129 MIC levels against 321 *C. gattii* isolates. VT-1129 MICs using the 50% inhibition of growth endpoint are shown by the gray bars and 100% inhibition by the white bars, and fluconazole MICs at 50% inhibition are shown by the black bars.

of growth was the endpoint used. The fluconazole MICs for isolates tested at the CDC had been previously determined (8), while fluconazole and VT-1129 susceptibility testing procedures were performed concurrently at UTHSCSA. Quality control isolates *Candida parapsilosis* ATCC 22019 and *Candida krusei* ATCC 6058 were included on each day of testing. The MIC range, modal MIC, MIC<sub>50</sub>, MIC<sub>90</sub>, and geometric mean (GM) MIC values were determined. The differences in GM MIC values were assessed for significance by a paired *t* test. *P* values of <0.05 were considered significant.

Overall, VT-1129 demonstrated potent activity against *C. neoformans* with MIC values ranging between ≤0.015 and 2 μg/ml at

**TABLE 1** VT-1129 and fluconazole MICs against *Cryptococcus neoformans* isolates<sup>a</sup>

Parameter	MIC for agent (endpoint)				UTHSCSA MIC over lower concn range of VT-1129 (n = 54)			
	VT-1129 (50%)	VT-1129 (100%)	FLU (50%)	FLU (50%)	VT-1129 (50%)	VT-1129 (100%)	FLU (50%)	FLU (50%)
Range	≤0.015–2	≤0.015–4	0.25–>64	0.25–>64	≤0.015–0.125	≤0.015–2	0.5–16	0.5–16
Mode	≤0.015	0.25	2	2	≤0.015	0.5	4	2
MIC <sub>50</sub>	≤0.015	0.25	2	2	≤0.015	0.25	2	2
MIC <sub>90</sub>	0.06	0.5	8	8	0.06	0.5	8	8
GM MIC <sup>b</sup>	0.0271	0.2052	2.280	2.280	0.0264	0.2997	2.250	2.317
								0.0126
								0.1519
								2.488

<sup>a</sup> All MICs were measured after 72 h of incubation at 35°C. VT-1129 MICs were read at 50% and 100% inhibition of growth compared to growth control. Fluconazole (FLU) MICs were measured at 50% inhibition of growth. Fluconazole MICs for CDC isolates are historical values.

<sup>b</sup> GM MIC, geometric mean MIC.

TABLE 2 VT-1129 MICs against *Cryptococcus gattii* isolates<sup>a</sup>

Parameter	MIC for agent (endpoint)					
	Cumulative (n = 321)		CDC (n = 300)		UTHSCSA (n = 21)	
	VT-1129 (50%)	VT-1129 (100%)	VT-1129 (50%)	VT-1129 (100%)	VT-1129 (50%)	VT-1129 (100%)
Range	≤0.015–1	0.06–>8	≤0.015–1	0.06–>8	≤0.015–0.25	0.06–1
Mode	0.125	1	0.25	1	0.125	0.25
MIC <sub>50</sub>	0.125	1	0.125	1	0.06	0.25
MIC <sub>90</sub>	0.25	2	0.25	2	0.125	0.5
GM MIC <sup>b</sup>	0.0782	0.7573	0.0804	0.8112	0.0534	0.2842

<sup>a</sup> All MICs were measured after 72 h of incubation at 35°C and read at 50% and 100% inhibition of growth compared to growth control.

<sup>b</sup> GM MIC, geometric mean MIC.

the 50% inhibition of growth endpoint and between ≤0.015 and 4 μg/ml at the 100% endpoint (Table 1). VT-1129 was also significantly more potent than fluconazole against *C. neoformans*, as evident by the lower MIC range and MIC<sub>50</sub> and MIC<sub>90</sub> values. In addition, the VT-1129 GM MICs at both the 50% and 100% inhibition endpoints (0.0271 and 0.2052 μg/ml, respectively) were significantly lower than that of fluconazole (2.280 μg/ml; *P* < 0.001). The MIC distributions for VT-1129 and fluconazole against the *C. neoformans* isolates are shown in Fig. 2A and B. Against the 31 isolates with elevated fluconazole MICs (≥8 μg/ml based on the MIC<sub>90</sub> value for this azole), VT-1129 maintained potent activity. With the 50% inhibition endpoint, the VT-1129 MIC<sub>50</sub>, MIC<sub>90</sub>, and GM MIC values were 0.030, 0.125, and 0.0506 μg/ml, respectively, while at the 100% inhibition endpoint, these values were 0.5, 1, and 0.3818 μg/ml. The *in vitro* potency observed with VT-1129 against *C. neoformans* clinical isolates was also consistent between the two laboratories with similar MIC<sub>50</sub>, MIC<sub>90</sub>, and GM MIC values. In fact, the modal MIC and MIC<sub>50</sub> values using the 50% inhibition endpoint were both ≤0.015 μg/ml for each laboratory. Because many of the VT-1129 MICs were below the lowest concentration tested, another group of 54 clinical isolates, with no overlap with the first group, was tested at UTHSCSA using a lower concentration range (0.0005 to 0.25 μg/ml). As shown in Table 1, the modal MIC, MIC<sub>50</sub>, and GM MIC values were lower with the 50% inhibition endpoint at this lower concentration range than at the higher concentration range (0.015 to 8 μg/ml).

Potent *in vitro* activity was also observed for VT-1129 against *C. gattii* with MIC values ranging between ≤0.015 and 1 μg/ml at the 50% inhibition of growth endpoint and between 0.06 and >8 μg/ml at the 100% endpoint (Table 2 and Fig. 2C). Similar to the results observed against *C. neoformans*, the potency of VT-1129 against *C. gattii* was observed by both laboratories, although the values were somewhat higher for the isolates tested at the CDC. This may be a reflection of the larger number of strains that were tested by this laboratory (*n* = 300) than were tested at UTHSCSA (*n* = 21). Previous studies have shown that *C. gattii* antifungal susceptibility patterns vary according to the molecular type of the isolate, with VGII isolates generally having higher azole MIC values. This was largely true for VT-1129 as well. At 50% inhibition, the MIC<sub>50</sub>, MIC<sub>90</sub>, and GM MIC values for VGIV isolates were the lowest (0.015, 0.06, and 0.0253 μg/ml, respectively) followed by those for the VGI isolates (0.03, 0.125, and 0.0432 μg/ml, respectively) (Table 3). The VGII isolates and VGIII isolates had the highest MIC<sub>50</sub>, MIC<sub>90</sub>, and GM MIC values, but they were only 1 to 3 dilutions higher than those of the VGI isolates. Similar results

TABLE 3 VT-1129 MICs against *Cryptococcus gattii* isolates by molecular type<sup>a</sup>

Endpoint	MIC (μg/ml)	
	50%	100%
VGI (n = 45)		
Range	≤0.015–0.5	0.125–8
Mode	0.015	0.25
MIC <sub>50</sub>	0.03	0.5
MIC <sub>90</sub>	0.125	1
GM MIC <sup>b</sup>	0.0432	0.4019
VGII (n = 7)		
Range	0.06–0.25	0.5–2
Mode	0.25	0.5–1
MIC <sub>50</sub>	0.25	1
MIC <sub>90</sub>	0.25	1
GM MIC	0.1506	0.8203
VGIIa (n = 104)		
Range	0.06–0.5	0.5–2
Mode	0.125	1
MIC <sub>50</sub>	0.125	1
MIC <sub>90</sub>	0.25–2	2
GM MIC	0.1332	0.9477
VGIIb (n = 20)		
Range	0.06–0.5	0.5–2
Mode	0.125–0.25	2
MIC <sub>50</sub>	0.125	2
MIC <sub>90</sub>	0.25	2
GM MIC	0.1761	1.319
VGIIc (n = 32)		
Range	0.06–1	0.5–4
Mode	0.25	2
MIC <sub>50</sub>	0.25	2
MIC <sub>90</sub>	0.25	2
GM MIC	0.2187	1.874
VGIII (n = 20)		
Range	≤0.015–0.25	0.25–2
Mode	0.125	1
MIC <sub>50</sub>	0.125	1
MIC <sub>90</sub>	0.25	1
GM MIC	0.1111	0.8123
VGIV (n = 72)		
Range	≤0.015–0.25	0.125–>8
Mode	0.015	0.5
MIC <sub>50</sub>	0.015	0.5
MIC <sub>90</sub>	0.06	2
GM MIC	0.0253	0.6019

<sup>a</sup> All MICs were measured after 72 h of incubation at 35°C. VT-1129 MICs were read at 50% and 100% inhibition of growth compared to growth control.

<sup>b</sup> GM MIC, geometric mean MIC.

were also observed when the 100% growth inhibition endpoint was used.

In summary, VT-1129 demonstrated excellent *in vitro* activity against *Cryptococcus* species, including members of the *C. neoformans* and *C. gattii* species complexes. This activity was also maintained against isolates with reduced susceptibility to fluconazole. Although VT-1129 was not directly compared to antifungals other than fluconazole, its activities against *Cryptococcus* species were similar to those previously reported for amphotericin B and the extended spectrum azoles, posaconazole, voriconazole, and isavuconazole (13–18). These data suggest that VT-1129 may be a promising agent against *Cryptococcus* species. VT-1129 phase 1 studies are now under way to establish the safety and pharmacokinetic profile necessary for phase 2 studies in patients with cryptococcal meningitis.

## ACKNOWLEDGMENTS

N.P.W. has received research support from Astellas, bioMérieux, Dow, F2G, Merck, Merz, Revolution Medicines, and Viamet and has served on advisory boards for Merck, Astellas, Toyama, and Viamet. T.F.P. has received research grants to UT Health Science Center San Antonio from Astellas, Merck, and Revolution Medicines and has served as a consultant for Astellas, Gilead, Merck, Pfizer, Revolution Medicines, Scynexis, Toyama, Viamet, and Vical. E.P.G., S.R.B., W.J.H., and R.J.S. are employees of Viamet Pharmaceuticals, Inc. The other authors declare no conflicts of interest.

## FUNDING INFORMATION

This project was funded by the National Institutes of Health National Institute of Allergy and Infectious Diseases under contract no. N01-AI-25475 (Thomas F. Patterson), the National Institutes of Health, National Center for Advancing Translational Sciences, Therapeutics for Rare and Neglected Diseases (TRND) Program (Shawn R. Lockhart), and Viamet Pharmaceuticals, Inc. (Nathan P. Wiederhold). VT-1129 powder was provided by Viamet Pharmaceuticals, Inc.

## REFERENCES

- Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by The Infectious Diseases Society of America. *Clin Infect Dis* 50:291–322. <http://dx.doi.org/10.1086/649858>.
- Chayakulkeeree M, Perfect JR. 2006. Cryptococcosis. *Infect Dis Clin North Am* 20:507–544, v–vi. <http://dx.doi.org/10.1016/j.idc.2006.07.001>.
- Li SS, Mody CH. 2010. Cryptococcus. *Proc Am Thorac Soc* 7:186–196. <http://dx.doi.org/10.1513/pats.200907-063AL>.
- Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. 2009. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. *AIDS* 23:525–530. <http://dx.doi.org/10.1097/QAD.0b013e3283222fac>.
- Hoekstra WJ, Garvey EP, Moore WR, Rafferty SW, Yates CM, Schotzinger RJ. 2014. Design and optimization of highly-selective fungal CYP51 inhibitors. *Bioorg Med Chem Lett* 24:3455–3458. <http://dx.doi.org/10.1016/j.bmcl.2014.05.068>.
- Warrilow AG, Hull CM, Parker JE, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Kelly DE, Kelly SL. 2014. The clinical candidate VT-1161 is a highly potent inhibitor of *Candida albicans* CYP51 but fails to bind the human enzyme. *Antimicrob Agents Chemother* 58:7121–7127. <http://dx.doi.org/10.1128/AAC.03707-14>.
- Garvey EP, Hoekstra WJ, Schotzinger RJ, Fothergill AW, Wiederhold NP, Warrilow AGS, Kelly DE, Kelly SL. 2015. VT-1129 binds potently and selectively to recombinant cryptococcal CYP51 consistent with its potent *in vitro* anti-cryptococcal activity, poster M-848. Abstr 55th Intersci Conf Antimicrob Agents Chemother, San Diego, CA.
- Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR. 2011. Trends in antifungal drug susceptibility of *Cryptococcus neoformans* isolates obtained through population-based surveillance in South Africa in 2002–2003 and 2007–2008. *Antimicrob Agents Chemother* 55:2606–2611. <http://dx.doi.org/10.1128/AAC.00048-11>.
- Lockhart SR, Iqbal N, Bolden CB, DeBess EE, Marsden-Haug N, Worhle R, Thakur R, Harris JR. 2012. Epidemiologic cutoff values for triazole drugs in *Cryptococcus gattii*: correlation of molecular type and *in vitro* susceptibility. *Diagn Microbiol Infect Dis* 73:144–148. <http://dx.doi.org/10.1016/j.diagmicrobio.2012.02.018>.
- Iqbal N, DeBess EE, Wohrle R, Sun B, Nett RJ, Ahlquist AM, Chiller T, Lockhart SR. 2010. Correlation of genotype and *in vitro* susceptibilities of *Cryptococcus gattii* strains from the Pacific Northwest of the United States. *J Clin Microbiol* 48:539–544. <http://dx.doi.org/10.1128/JCM.01505-09>.
- Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, Esposto MC, Fisher M, Gilgado F, Hagen F, Kaocharoen S, Litvintseva AP, Mitchell TG, Simwami SP, Trilles L, Viviani MA, Kwon-Chung J. 2009. Consensus multi-locus sequence typing scheme for *Cryptococcus neoformans* and *Cryptococcus gattii*. *Med Mycol* 47:561–570. <http://dx.doi.org/10.1080/13693780902953886>.
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
- Thompson GR, III, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. 2009. Antifungal susceptibilities among different serotypes of *Cryptococcus gattii* and *Cryptococcus neoformans*. *Antimicrob Agents Chemother* 53:309–311. <http://dx.doi.org/10.1128/AAC.01216-08>.
- Yildiran ST, Fothergill AW, Sutton DA, Rinaldi MG. 2002. *In vitro* susceptibilities of cerebrospinal fluid isolates of *Cryptococcus neoformans* collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). *Mycoses* 45:378–383. <http://dx.doi.org/10.1046/j.1439-0507.2002.00765.x>.
- Trilles L, Fernandez-Torres B, dos Santos Lazera M, Wanke B, Guarro J. 2004. *In vitro* antifungal susceptibility of *Cryptococcus gattii*. *J Clin Microbiol* 42:4815–4817. <http://dx.doi.org/10.1128/JCM.42.10.4815-4817.2004>.
- Thompson GR, III, Fothergill AW, Wiederhold NP, Vallor AC, Wickes BL, Patterson TF. 2008. Evaluation of Etest method for determining isavuconazole MICs against *Cryptococcus gattii* and *Cryptococcus neoformans*. *Antimicrob Agents Chemother* 52:2959–2961. <http://dx.doi.org/10.1128/AAC.00646-08>.
- Guinea J, Hagen F, Pelaez T, Boekhout T, Tahoune H, Torres-Narbona M, Bouza E. 2010. Antifungal susceptibility, serotyping, and genotyping of clinical *Cryptococcus neoformans* isolates collected during 18 years in a single institution in Madrid, Spain. *Med Mycol* 48:942–948. <http://dx.doi.org/10.3109/13693781003690067>.
- Hagen F, Illnait-Zaragozi MT, Bartlett KH, Swinne D, Geertsens E, Klaassen CH, Boekhout T, Meis JF. 2010. *In vitro* antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental *Cryptococcus gattii* isolates. *Antimicrob Agents Chemother* 54:5139–5145. <http://dx.doi.org/10.1128/AAC.00746-10>.